Printer Friendly

Team bringing hope to kidney disease sufferers; PATIENTS WITH FAULTY GENE COULD RECEIVE PERSONALISED TREATMENT.

Byline: KATIE DICKINSON Reporter katie.dickinson@ncjmedia.co.uk

PATIENTS with a life-limiting genetic condition have been given new hope after a breakthrough by Newcastle scientists.

For the first time researchers have identified how to halt kidney disease in Joubert syndrome, which may pave the way for personalised treatment in the future.

Experts at Newcastle University have shown in a cell model and in a mouse model that gene editing could be used for Joubert syndrome to stop kidney damage in patients who have the CEP290 faulty gene.

Joubert syndrome is a brain disorder, causing varying degrees of physical, mental and sometimes visual impairments The condition affects approximately one in 80,000 newborns, and one third also get kidney failure.

Not all patients with Joubert syndrome carry the CEP290 gene, but those who do will develop kidney disease during their lifetime and may require a transplant or dialysis.

The research has found it is possible to use a strand of engineered DNA to trick the cells' own editing machinery to bypass the CEP290 mutation that causes kidney damage - a technique known as 'exon-skipping.'.

Professor John Sayer, from the Institute of Genetic Medicine at Newcastle University, led the research. He said: "This is the first time that gene editing within the kidney has been performed, even in a mouse model, as the design and delivery of the gene editing to the kidney has previously been thought to be too difficult. Our research is a major step forward as we now know how we may be able to offer a therapy that corrects the gene mistake within kidney cells and prevent the development of genetic kidney disease. This work paves the way towards personalised genetic therapies in patients with the inherited kidney disease."

The European study used kidney cells from patients with Joubert syndrome and a mouse model to progress the research. Experts used urine samples to grow kidney cells in the laboratory to see how the cells responded to gene editing. They also performed gene editing to halt kidney disease in a mouse that had Joubert syndrome and rodents suffering from kidney cysts and kidney failure.

Professor Sayer, a consultant nephrologist at Newcastle Hospitals NHS Foundation Trust, said: "We have shown that the kidney disease in a mouse can be dramatically improved using this exon-skipping gene editing technology. This will mean that we can edit out genetic mistakes that are leading to inherited kidney diseases such as Joubert syndrome and we are testing this technology in other mouse models before we move into patient studies.

"We expect that we will start to test treatment of patients with exon-skipping within the next three years." Teenager Asher Ahmed has Joubert syndrome and is likely to need a kidney transplant in the future. Asher, of Fenham, Newcastle, was diagnosed with kidney damage five years ago and is on a number of drugs to keep him well.

The 19-year-old has a range of medical issues due to his Joubert syndrome, including visual impairment, communication problems and difficulties with balance and coordination. The teenager has provided samples over the years, allowing the scientists to grow kidney cells. Asher's mother, Nabila, welcomed the findings, saying: "This will hopefully prevent patients in the future needing a kidney transplant."

Asher Ahmed

CAPTION(S):

Professor John Sayer, from the Institute of Genetic Medicine, Newcastle University

Asher Ahmed
COPYRIGHT 2018 MGN Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Evening Chronicle (Newcastle, England)
Date:Nov 19, 2018
Words:557
Previous Article:Jones heaps his praise on Cokanasiga; RUGBY UNION.
Next Article:We can still reduce costs without jeopardising public safety; fire service boss moves to defend proposed PS3.5m cuts.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters